Mereuţă A, Turtureanu-Hanganu E
Clinica a III-a medicală, Institutul de Medicină şi Farmacie Iaşi.
Rev Med Chir Soc Med Nat Iasi. 1990 Jan-Mar;94(1):67-73.
A series of 27 patients with myelodysplastic syndrome (MDS) was analysed to determine the clinical and pathologic features, the natural history and the prognostic factors. The clinical features of these patients included the following: mean age 53.77 years; symptoms due to cytopenias 100 per cent; hepatomegaly 44.5 per cent; splenomegaly 11 per cent. Almost all patients with MDS presented anemia; additional cytopenias were present in many patients. The bone marrow was hypocellular in 1/3 of cases. The patients have been classified according to the French-American-British (FAB) Group criteria: there were 11 patients with refractory anemia, 11 patients with refractory anemia with sideroblasts and 5 patients with refractory anemia with excess of blasts. The mean survival was 19 months, 9 patients died: death was due to infection or hemorrhage in 7 cases and to evolution to acute myelogenous leukemia (AML) in 2 cases (10.5%). Thrombocytopenia, the Bournemouth scoring system and FAB classification were independent prognostic factors.
对27例骨髓增生异常综合征（MDS）患者进行了分析，以确定其临床和病理特征、自然病史及预后因素。这些患者的临床特征如下：平均年龄53.77岁；100%的患者有血细胞减少相关症状；44.5%的患者有肝肿大；11%的患者有脾肿大。几乎所有MDS患者都有贫血；许多患者还存在其他血细胞减少。1/3的病例骨髓细胞减少。根据法国-美国-英国（FAB）组标准对患者进行了分类：11例难治性贫血患者，11例伴有环形铁粒幼细胞的难治性贫血患者，5例伴有原始细胞增多的难治性贫血患者。平均生存期为19个月，9例患者死亡：7例死于感染或出血，2例（10.5%）死于进展为急性髓系白血病（AML）。血小板减少、伯恩茅斯评分系统和FAB分类是独立的预后因素。
